All Clinical Trials

Locations
Conditions
Treatments
Institutions
Resources
For researchers

< Back to search

Terms of use Privacy policy

All Clinical Trials 2024All Rights reservedPrivacy Policy Terms of Use

Locations Texas Arizona California New York Massachusetts Florida New Jersey Utah All locationsConditions Oncology Alzheimer's Diabetes Multiple Sclerosis Arthritis Hepatitis C COPD Depression All conditionsTreatments Weight Loss Stem Cells Vaccines Sleep Apnea Medical Devices IVF Dental Drug Addiction All treatmentsInstitutions Pfizer Moderna NIH UCLA Stanford M.D. Anderson Labcorp All institutionsResourcesBlog FAQ Medical advisors

Terms of use Privacy policy

All Clinical Trials 2024All Rights reservedPrivacy Policy Terms of Use

NCT05620836

e.g. Massachusetts•Healthy volunteers: No

Filter results

Condition

State

City

Age

Healthy volunteers

Allowed

Results: 1

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

PHASE3

Sponsor:

Incyte Corporation

Location:

St. John's, Scottsdale, Arkansas, Fayettevilleshow 40 more

Code:

NCT05620836

Conditions

Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Povorcitinib

Placebo